Wells Fargo Maintains Overweight on GeneDx Holdings, Lowers Price Target to $75

Benzinga Newsdesk www.benzinga.com Negative 77.0%

Neg 77% Neu 0% Pos 0%

Wells Fargo analyst Brandon Couillard maintains GeneDx Holdings (NASDAQ:WGS) with a Overweight and lowers the price target from $155 to $75.